Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020.
Tekijät: Harvala H, Mehew J, Robb ML, Ijaz S, Dicks S, Patel M, Watkins N, Simmonds P, Brooks T, Johnson R, Gopal R, Roberts DJ, Zambon M, NHS Blood and Transplant Convalescent Plasma Testing Group
Julkaisuvuosi: 2020
Journal: Eurosurveillance
Tietokannassa oleva lehden nimi: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
Lehden akronyymi: Euro Surveill
Vuosikerta: 25
Numero: 28
ISSN: 1025-496X
eISSN: 1560-7917
DOI: https://doi.org/10.2807/1560-7917.ES.2020.25.28.2001260
Tiivistelmä
Serological reactivity was analysed in plasma from 436 individuals with a history of disease compatible with COVID-19, including 256 who had been laboratory-confirmed with SARS-CoV-2 infection. Over 99% of laboratory-confirmed cases developed a measurable antibody response (254/256) and 88% harboured neutralising antibodies (226/256). Antibody levels declined over 3 months following diagnosis, emphasising the importance of the timing of convalescent plasma collections. Binding antibody measurements can inform selection of convalescent plasma donors with high neutralising antibody levels.
Serological reactivity was analysed in plasma from 436 individuals with a history of disease compatible with COVID-19, including 256 who had been laboratory-confirmed with SARS-CoV-2 infection. Over 99% of laboratory-confirmed cases developed a measurable antibody response (254/256) and 88% harboured neutralising antibodies (226/256). Antibody levels declined over 3 months following diagnosis, emphasising the importance of the timing of convalescent plasma collections. Binding antibody measurements can inform selection of convalescent plasma donors with high neutralising antibody levels.
Turun yliopiston Tutkimustietojärjestelmän portaali